Ad lib.

Add Libtayo (aka cemiplimab) to the remarkably short list of approved drugs targeting PD-1. Last week cemiplimab became the third PD-1 inhibitor to earn FDA-approval for any indication and the very first systemic therapy to earn approval for the treatment of advanced cutaneous squamous cell carcinoma following early reports of noteworthy responses. | American Cancer Society 2018